KRAS Inhibitors Market Size, Share & Industry Analysis, By Drug (Sotorasib, Adagrasib, Divarasib, Olomorasib, RMC-6236, KRAS G12D Inhibitors, and Others), By Disease Indication (Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, and Others), By Age Group (Pediatric and Adults), By Type (KRAS G12C Inhibitors, KRAS G12D Inhibitors, and Others), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail & Drug Store Pharmacies, and Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: July 03, 2026 | Format: PDF | Report ID: FBI117951

Buy Now

To get information on various segments, share your queries with us

ATTRIBUTE	DETAILS
Study Period	2021-2034
Base Year	2025
Estimated Year	2026
Forecast Period	2026-2034
Historical Period	2021-2024
Growth Rate	CAGR of 13.01% from 2026 to 2034
Unit	Value (USD Million)
Segmentation	By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region
By Drug	Sotorasib Adagrasib Divarasib Olomorasib RMC-6236 KRAS G12D Inhibitors Others
By Disease Indication	Non-Small Cell Lung Cancer Colorectal Cancer Pancreatic Cancer Biliary Tract Cancer Others
By Age Group	Adults Pediatric
By Type	KRAS G12C Inhibitors KRAS G12D Inhibitors Others
By Route of Administration	Oral Parenteral
By Distribution Channel	Hospital Pharmacies Specialty Pharmacies Retail & Drug Store Pharmacies Online Pharmacies
By Region	North America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country) U.S. Canada Europe (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region) Germany U.K. France Spain Italy Scandinavia Rest of Europe Asia Pacific (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region) China Japan India Australia Southeast Asia Rest of Asia Pacific Latin America (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region) Brazil Mexico Rest of Latin America Middle East & Africa (By Drug, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region) GCC South Africa Rest of Middle East & Africa